Genetics, Genomics and Precision Oncology (2026): The Ultimate Guide to Precision Oncology, Targeted Therapy, and the Future of Cancer Treatment

Home  ›  Precision Oncology  ›  Genomics vs. Genetics in Cancer

Updated July 2026  |  Reflects ASCO 2026 & AACR 2026 data

Quick Answer

Genetics studies individual genes — especially inherited mutations like BRCA1/BRCA2 — to assess hereditary cancer risk. Genomics studies a tumor's entire DNA blueprint, including both inherited and acquired mutations, and is the foundation of precision oncology: using next-generation sequencing, liquid biopsy, and increasingly AI-assisted analysis to match each patient's tumor with the targeted therapy, immunotherapy, or monitoring strategy most likely to work for them.

Key Takeaways

• Genetics examines individual genes and inherited risk; genomics examines a tumor's entire molecular landscape, acquired mutations included.
• Cancer is now classified primarily as a genomic disease, not simply a disease of an organ.
• 2026 has been described by ASCO as precision oncology's "implementation era" — the science exists; the challenge is delivering it at scale.
• Minimal residual disease (MRD) blood tests are now an FDA-recognized companion diagnostic that can guide de-escalation of chemotherapy in specific cancers.
• The phase 3 OPTIMA trial (ASCO 2026) showed a 50-gene genomic test could identify roughly two-thirds of high-risk breast cancer patients who gain little added benefit from chemotherapy.
• Personalized mRNA neoantigen vaccines produced five-year randomized data in melanoma at ASCO 2026, alongside earlier-stage but encouraging pancreatic cancer results.
• AI is being used to predict treatment response, but only a handful of models are FDA-cleared and validated; most remain investigational.
• Cost, data complexity, and unequal access remain the biggest barriers between genomic discovery and patients actually receiving matched therapy.

Table of Contents

1. Introduction: Why Cancer Is a Genomic Disease
2. Genetics vs. Genomics: Key Differences
3. The Genomic Hallmarks of Cancer
4. Types of Genomic Alterations in Cancer
5. Tumor Heterogeneity and Clonal Evolution
6. Next-Generation Sequencing: The Engine of Precision Oncology
7. Clinical Applications of Cancer Genomics
8. 2026 Frontiers: AI, Multi-Omics, Vaccines & Single-Cell Sequencing
9. Evidence Snapshot: How Strong Is the 2026 Data?
10. Limitations and Challenges
11. The Future of Cancer Treatment
12. Frequently Asked Questions
13. Using AI Assistants to Research Cancer Genomics
14. References

Introduction: Why Cancer Is a Genomic Disease

Cancer is no longer defined as simple uncontrolled cell growth. It is understood as a disease of the genome — driven by accumulated mutations, structural DNA rearrangements, and epigenetic changes that disrupt the normal rules governing when a cell divides, repairs itself, or dies.

Two decades of progress in sequencing technology have pushed oncology away from classifying tumors purely by organ of origin — lung, breast, colon — and toward classifying them by their molecular and genomic characteristics. That shift is what clinicians and researchers now call precision oncology: a model where diagnosis, prognosis, and treatment selection are guided by the specific genetic and molecular makeup of an individual patient's tumor.

Cancer genomics today allows clinicians to:

• Identify driver mutations that actively fuel tumor growth, and distinguish them from passenger mutations with little biological consequence
• Predict which therapies are most likely to work before a patient ever starts treatment
• Monitor for relapse months earlier than imaging alone would detect it

Large sequencing consortia have confirmed a fact that shapes everything else in this article: even patients with the same diagnosis have genomically unique tumors. That reality complicates one-size-fits-all treatment, but it is also exactly what makes highly personalized therapy possible.

According to ASCO's 2026 Annual Meeting commentary, precision oncology has entered an "implementation era." The scientific insights — new biomarkers, better assays, more actionable mutations — increasingly outpace the health system's ability to deliver them consistently to patients at the point of care. ^{[Ref. 74]}

Genetics vs. Genomics: Key Differences

The two terms are often used interchangeably, but they describe different scopes of analysis.

Cancer Genetics

Cancer genetics focuses on individual genes, particularly inherited mutations passed down through families. Classic examples:

• BRCA1 / BRCA2 — elevated breast and ovarian cancer risk
• Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2) — elevated colorectal and endometrial cancer risk
• TP53 mutations in Li-Fraumeni syndrome

Genetic testing for inherited mutations is used to identify high-risk individuals, guide earlier or more frequent screening, and inform preventive options such as risk-reducing surgery or chemoprevention.

Cancer Genomics

Cancer genomics examines the entire genome of the tumor — inherited changes plus acquired (somatic) ones — including point mutations, copy number variations, structural rearrangements, and epigenetic modifications. This systems-level view underpins precision medicine, targeted therapy selection, and biomarker discovery.

Dimension	Genetics	Genomics
Scope	One gene or a small set of genes	The entire genome, or a broad panel of genes
Origin of mutation	Primarily inherited (germline)	Inherited (germline) and acquired (somatic)
Main clinical use	Hereditary risk assessment, screening, prevention	Tumor profiling, targeted therapy selection, monitoring
Typical test	Germline genetic test (blood or saliva)	Tumor tissue NGS panel, liquid biopsy, MRD assay
Example question answered	"Am I at higher inherited risk of cancer?"	"What mutations are driving my specific tumor, and what treats them?"

The Genomic Hallmarks of Cancer

Cancer develops through a sequence of genomic changes that give cells specific survival advantages — the "hallmarks of cancer" framework first proposed by Hanahan and Weinberg. ^{[Ref. 1]} These include:

• Sustained proliferative signaling, often via oncogene activation (e.g., KRAS)
• Resistance to cell death, through disrupted apoptosis pathways
• Immune evasion, via checkpoint mechanisms like PD-L1
• Replicative immortality, through telomere maintenance
• Angiogenesis, building a tumor's own blood supply
• Invasion and metastasis, allowing spread to distant organs

Each hallmark traces back to a specific genomic disruption: oncogene activation drives continuous division, loss of tumor suppressors like TP53 impairs DNA repair, and epigenetic silencing can switch off genes that would otherwise flag the cell to the immune system. Cancer progression is not random — it is an evolutionary process, in which mutations conferring a survival advantage are selected for over time.

Types of Genomic Alterations in Cancer

Point Mutations

Single nucleotide changes — common in genes like KRAS and TP53 — that can activate oncogenes or deactivate tumor suppressors, often as early events in tumor development.

Copy Number Variations (CNVs)

Gains or losses of large DNA segments. Amplification can overexpress oncogenes such as HER2; deletion can knock out tumor suppressors such as PTEN.

Structural Variants

Large-scale chromosomal changes. Translocations can fuse two genes together — the BCR-ABL fusion in chronic myeloid leukemia being the textbook example — creating a novel, often highly druggable target.

Epigenetic Alterations

Changes to gene expression that don't alter the DNA sequence itself — DNA methylation, histone modification, chromatin remodeling. These can silence protective genes or switch on harmful pathways.

Mutational Signatures

Patterns of DNA damage that point back to a cause: UV damage in skin cancer, tobacco-related signatures in lung cancer, mismatch-repair defects in certain colorectal cancers. ^{[Ref. 3]}

Related: How to Read a Cancer Genomic & Biomarker Report: A Patient's Guide to Precision Oncology

Tumor Heterogeneity and Clonal Evolution

One of oncology's toughest problems is how much a single tumor can vary internally and between patients:

• Intra-tumor heterogeneity — different regions of the same tumor carry distinct genomic profiles
• Inter-tumor heterogeneity — two patients with an identical diagnosis can have entirely different genomic landscapes

Clinically, this produces variable treatment responses, drug resistance, and high relapse rates. It happens through clonal evolution: an initial mutation seeds a tumor clone, further mutations accumulate, treatment kills off sensitive cells, and resistant clones survive and expand. This is the core reason many cancers respond initially to therapy and later recur. ^{[Ref. 43, 44]}

Next-Generation Sequencing: The Engine of Precision Oncology

Next-generation sequencing (NGS) sequences millions of DNA fragments in parallel, which is what made large-scale genomic profiling fast and affordable enough for everyday clinical use.

Whole Genome Sequencing

Analyzes essentially all DNA and detects the broadest range of alterations, but remains the most costly and computationally intensive option.

Whole Exome Sequencing

Focuses on the protein-coding regions — roughly 1 to 2 percent of the genome — offering a cost-effective middle ground widely used in research and some clinical settings.

Targeted Gene Panels

Focus only on clinically actionable genes. These are the fastest, most affordable, and most commonly used option in routine clinical practice today.

A notable 2026 trend highlighted at ASCO's Annual Meeting is decentralized, point-of-care NGS. Platforms such as the Ion Torrent Oncomine Dx Express Test are designed to bring genomic testing capability into local labs rather than requiring samples to be shipped to a small number of centralized reference labs — aiming to shorten the time between biopsy and an actionable result. ^{[Ref. 74]}

Clinical Applications of Cancer Genomics

Risk Assessment and Prevention

Germline genetic testing identifies people at elevated inherited risk, enabling earlier or more targeted screening, preventive options such as surgery or medication, and more personalized lifestyle guidance.

Precision Diagnosis

Genomics improves diagnostic accuracy — classifying tumors by molecular subtype, identifying rare or ambiguous cancers, and distinguishing a primary tumor from a metastasis of a different origin.

Targeted Therapy — and Genomic-Guided De-Escalation

Targeted therapies inhibit specific molecular drivers rather than all rapidly dividing cells. Established examples include EGFR inhibitors in lung cancer, HER2-targeted therapies in breast cancer, BRAF inhibitors in melanoma, and KRAS G12C inhibitors in certain solid tumors.

A 2026 development worth understanding is genomic testing being used not just to select a drug, but to safely de-escalate treatment. The phase 3 OPTIMA trial, presented at ASCO 2026, used the Prosigna (PAM50) 50-gene assay in patients with clinically high-risk, ER-positive/HER2-negative early breast cancer. About 68% of enrolled patients had a low genomic Risk-of-Recurrence score, and in that group, five-year invasive breast-cancer-free survival was similar whether or not chemotherapy was added to endocrine therapy — suggesting many of these patients gained little from chemotherapy despite their clinical risk profile. ^{[Ref. 75, 76]}

Important context: current NCCN guidance for this setting has generally favored a different assay (Oncotype DX), and oncologists interviewed about OPTIMA have noted that longer follow-up and further validation are needed before test-directed chemotherapy avoidance becomes routine practice with Prosigna specifically. This is a research result to discuss with an oncologist, not a standalone basis for a treatment decision.

Immunotherapy Optimization

Genomics helps identify who is more likely to benefit from immune checkpoint inhibitors, using biomarkers such as tumor mutational burden, microsatellite instability, and PD-L1 expression.

Liquid Biopsy, ctDNA, and MRD Monitoring

Liquid biopsy detects circulating tumor DNA (ctDNA) in a routine blood draw, enabling non-invasive genomic profiling, treatment-response monitoring, and earlier detection of recurrence than imaging alone typically allows.

This field moved from research tool to formal treatment-selection criterion in 2026:

• The FDA approved Signatera CDx for use with adjuvant atezolizumab in muscle-invasive bladder cancer — the first blood-based, tumor-informed MRD companion diagnostic approval, formally establishing MRD status as a regulatory endpoint for treatment de-escalation in solid tumors. ^{[Ref. 77]}
• The FDA also approved an expanded Guardant360 Liquid CDx panel, broadening the genomic footprint assessed from a single blood draw. ^{[Ref. 77]}
• Interim results from the large NHS-Galleri trial of GRAIL's multi-cancer early detection blood test were presented at ASCO 2026, reporting a reduction in stage IV cancer diagnoses among the screened population — though this remains an interim readout of an ongoing randomized trial, not a finalized, guideline-endorsed screening recommendation. ^{[Ref. 77, 78]}

2026 Frontiers: AI, Multi-Omics, Vaccines & Single-Cell Sequencing

Single-Cell Sequencing

Analyzing individual cancer cells rather than bulk tumor tissue helps identify resistant subclones, map interactions with the surrounding tumor microenvironment, and trace metastatic spread cell by cell.

Multi-Omics Integration

Combining genomics with transcriptomics, proteomics, and metabolomics gives a more complete picture of tumor biology than any single layer of data alone.

Artificial Intelligence in Oncology

AI is being applied across diagnosis, prognosis, and treatment-response prediction, but the maturity of these tools varies enormously:

• Artera AI Breast — an FDA-cleared multimodal AI model combining H&E slide images with clinical variables — was evaluated at ASCO 2026 using data from the SWOG 8814 trial, and produced a prognostic risk score that identified which node-positive, hormone-receptor-positive patients gained the most benefit from added chemotherapy. ^{[Ref. 79]}
• At AACR 2026, a deep-learning model called Path-IO (Pathology-driven Immunotherapy Optimization) was presented as a proof-of-concept tool aiming to predict immunotherapy benefit in lung cancer from routine pathology slides and DNA methylation data — promising, but still pre-clinical-validation. ^{[Ref. 80]}
• A computational pipeline called PERCEPTION used single-cell data to model how individual tumor cells might respond to 44 FDA-approved cancer drugs in a proof-of-concept study — an early research tool, not a clinical test. ^{[Ref. 81]}

The throughline: a handful of AI tools are genuinely validated and in clinical use; the majority of headline-making models remain investigational. Our companion article, AI Diagnostic Tools in Oncology: What Patients Should Know, goes deeper on how to tell the difference.

Personalized Neoantigen Vaccines

Personalized mRNA cancer vaccines are manufactured from an individual patient's own tumor-sequencing data, training the immune system to recognize mutation-specific neoantigens unique to that cancer. Two 2026 data readouts stand out:

• Melanoma: Five-year data from a randomized trial of the personalized mRNA vaccine mRNA-4157 (V940) combined with pembrolizumab, presented at ASCO 2026 and published in the Journal of Clinical Oncology, showed the combination reduced the long-term risk of melanoma recurrence or death by nearly half compared with pembrolizumab alone. A larger, expanded phase 3 program is underway. ^{[Ref. 82, 83]}
• Pancreatic cancer: Long-term phase 1 follow-up of a personalized mRNA vaccine (autogene cevumeran) developed with Memorial Sloan Kettering and BioNTech found that roughly 90% of patients whose immune systems responded to the vaccine were still alive up to six years later — a striking result in a cancer where five-year survival is historically around 13%, though this is early-phase, small-sample data still awaiting phase 2 confirmation. ^{[Ref. 84, 85]}

Epigenetic Therapies

Drugs targeting reversible changes in gene expression — DNA methylation inhibitors, histone-modifying agents — continue to show particular promise in cancers that have become resistant to other approaches.

Evidence Snapshot: How Strong Is the 2026 Data?

Headlines about "breakthroughs" rarely distinguish between a randomized phase 3 result and an early proof-of-concept. Using the Oxford Centre for Evidence-Based Medicine (CEBM) framework, here is how the major 2026 developments discussed above currently stack up:

Development	CEBM Tier	What that means
OPTIMA trial (Prosigna-guided chemo de-escalation, breast cancer)	Level 1b	Randomized phase 3 trial; awaiting longer follow-up and guideline uptake
Signatera CDx + atezolizumab MRD de-escalation (bladder cancer)	Level 1b	FDA-approved companion diagnostic grounded in phase 3 data
mRNA-4157 + pembrolizumab, 5-year melanoma data	Level 1b	Randomized phase 2b trial; confirmatory phase 3 ongoing
GRAIL Galleri / NHS-Galleri multi-cancer screening	Level 1b (interim)	Large RCT, but an interim readout — not yet a finalized screening recommendation
Artera AI Breast (FDA-cleared multimodal AI)	Level 2b	Retrospective validation in a prior randomized trial cohort (SWOG 8814)
Personalized pancreatic mRNA vaccine (autogene cevumeran)	Level 4	Small, uncontrolled phase 1 case series; encouraging but preliminary
AI pathomics models (Path-IO, PERCEPTION)	Level 5	Early proof-of-concept; not yet clinically validated or in patient care

CEBM tiers, simplified: Level 1 = randomized controlled trial or meta-analysis of RCTs; Level 2 = cohort study or retrospective validation; Level 4 = case series without a control group; Level 5 = mechanistic rationale or expert opinion / proof-of-concept.

Limitations and Challenges

Data Complexity

Genomic data is vast and requires advanced computational tools and trained specialists to interpret meaningfully.

Limited Actionability

Many detected mutations still have no matched therapy, and clinical evidence generation lags behind the pace of discovery.

Cost and Accessibility

Comprehensive genomic profiling, MRD assays, and multi-cancer screening blood tests remain expensive and are not uniformly covered or available worldwide — a gap ASCO's 2026 commentary specifically flagged as the central challenge of the "implementation era." ^{[Ref. 74]}

Ethical Considerations

Genetic privacy, incidental findings unrelated to the original test, and inconsistent quality across direct-to-consumer genetic tests all remain unresolved concerns.

The Future of Cancer Treatment

Cancer care continues moving toward a fully personalized model. Plausible near-term developments include broader routine use of comprehensive genomic profiling, more AI-assisted treatment decisions once tools clear prospective validation, continuous monitoring via liquid biopsy, and combination therapies adapted as a tumor evolves under treatment.

The guiding question in oncology is shifting from "What type of cancer do you have?" to "What mutations, and what immune context, are driving your specific cancer — and how is that changing over time?"

Conclusion

Cancer genomics has turned oncology into a precision science. Understanding a tumor's genetic blueprint helps clinicians diagnose more accurately, treat more effectively, and predict outcomes with more confidence than organ-based classification alone ever allowed. Real challenges remain — cost, access, and the gap between discovery and delivery chief among them — but the trajectory is clear: the future of cancer care runs through decoding, and increasingly acting on, the genome.

Looking for a specialist who practices genomically guided cancer care? Our Find Oncologists directory can help you locate precision oncology providers.

Frequently Asked Questions

What is the difference between genetics and genomics in cancer?

Genetics studies single genes, especially inherited mutations such as BRCA1/BRCA2 or the Lynch syndrome genes, to assess hereditary cancer risk. Genomics studies a tumor's entire DNA and RNA landscape — including both inherited and acquired (somatic) mutations — to guide diagnosis, prognosis, and treatment selection.

Is cancer a genetic disease or a genomic disease?

Modern oncology describes cancer primarily as a genomic disease. Inherited mutations account for an estimated 5 to 10 percent of cancers, while the large majority arise from acquired somatic mutations and genomic instability that build up over a person's lifetime.

What is precision oncology?

Precision oncology is an approach to cancer care that uses a tumor's molecular and genomic profile, rather than only its organ of origin, to choose the diagnostics, targeted therapies, and immunotherapies most likely to work for that individual patient.

What is next-generation sequencing and why does it matter for cancer care?

Next-generation sequencing (NGS) reads millions of DNA fragments in parallel, making comprehensive tumor profiling fast and affordable enough for routine clinical use. It underlies whole-genome sequencing, whole-exome sequencing, and the targeted gene panels used to match patients with therapies.

What is a liquid biopsy?

A liquid biopsy is a blood test that detects circulating tumor DNA, circulating tumor cells, or other tumor-derived material. It lets clinicians profile a cancer's genomics, monitor treatment response, and look for molecular relapse without a surgical tissue biopsy.

What is minimal residual disease (MRD) testing, and can it help patients avoid chemotherapy?

MRD testing uses tumor-informed ctDNA assays to detect microscopic cancer left behind after surgery or treatment. In 2026, the FDA approved the first blood-based MRD companion diagnostic, pairing Signatera with adjuvant atezolizumab in muscle-invasive bladder cancer, establishing MRD status as a formal criterion oncologists can use to guide treatment intensity. Whether this applies to a given patient is cancer-type-specific and should be discussed with an oncologist.

What is the difference between whole-genome sequencing, whole-exome sequencing, and a targeted gene panel?

Whole-genome sequencing analyzes nearly all DNA and detects the widest range of alterations but costs the most. Whole-exome sequencing analyzes only the protein-coding regions, about 1 to 2 percent of the genome, balancing cost and coverage. Targeted gene panels sequence a curated set of clinically actionable genes and are the fastest, most affordable, and most commonly used option in routine care.

Are AI diagnostic tools in oncology reliable?

Some are. A small number of multimodal AI pathology models are FDA-cleared and have been validated in randomized trial cohorts, such as models predicting chemotherapy benefit in breast cancer. Many others, including AI models that predict immunotherapy response from routine slides, remain investigational and are still undergoing prospective validation before they can guide treatment decisions on their own.

What is a personalized cancer vaccine?

A personalized, or neoantigen, cancer vaccine is manufactured from the sequencing data of an individual patient's own tumor, training the immune system to recognize mutation-specific proteins unique to that cancer. Five-year randomized data presented at ASCO 2026 showed a personalized mRNA vaccine combined with pembrolizumab nearly halved the risk of melanoma recurrence or death compared with immunotherapy alone; results in other cancer types, such as pancreatic cancer, remain earlier-stage.

Using AI Assistants to Research Cancer Genomics

More readers now start this kind of research inside an AI assistant rather than a search bar. If you're using Claude, ChatGPT, Gemini, or Perplexity to make sense of a pathology report or a new diagnosis, a few habits make the answers noticeably more useful:

Claude — Strong at working through a specific document. Paste the biomarker or genomic-alteration section of your own pathology or NGS report (with identifying details removed) and ask it to explain each term in plain language and note which alterations tend to be "actionable" versus not — while being explicit that it should not give you a treatment recommendation.

ChatGPT — Good for decoding acronyms and general mechanisms quickly. Ask it to state its confidence level and flag anything that may have changed since a specific date, since oncology drug approvals move fast.

Gemini — Useful when you want the most current news on a specific trial or approval, since it can draw on live search. Cross-check the date and trial phase it cites against the original journal or conference source.

Perplexity — Helpful for citation-dense comparisons across sources. Check that the underlying citations are peer-reviewed journals or regulatory filings rather than aggregator blogs before treating a claim as settled.

Whichever tool you use, none of them replace a conversation with your treating oncologist or a certified genetic counselor — they're a way to arrive at that conversation better informed, not a substitute for it.

References (Peer-Reviewed and Conference-Indexed Sources)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011.
2. Vogelstein B, et al. Cancer genome landscapes. Science. 2013.
3. Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013.
4. The Cancer Genome Atlas Research Network. Comprehensive molecular portraits of human tumors. Nature. 2012–2018 series.
5. International Cancer Genome Consortium. International network of cancer genome projects. Nature. 2010.
6. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013.
7. Stratton MR, et al. The cancer genome. Nature. 2009.
8. Kandoth C, et al. Mutational landscape across major cancer types. Nature. 2013.
9. Lawrence MS, et al. Mutational heterogeneity in cancer. Nature. 2013.
10. Bailey MH, et al. Comprehensive characterization of cancer driver genes. Cell. 2018.
11. Ding L, et al. Clonal evolution in relapsed acute myeloid leukemia. Nature. 2012.
12. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012.
13. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976.
14. Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem. 2013.
15. Metzker ML. Sequencing technologies: the next generation. Nat Rev Genet. 2010.
16. Goodwin S, et al. Coming of age: ten years of next-generation sequencing. Nat Rev Genet. 2016.
17. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008.
18. Rehm HL. Disease-targeted sequencing panels. Nat Rev Genet. 2013.
19. Roychowdhury S, Chinnaiyan AM. Translating genomics for precision oncology. Nat Rev Genet. 2016.
20. Dienstmann R, et al. Precision oncology: revolution or evolution? Nat Rev Clin Oncol. 2017.
21. Garraway LA. Genomics-driven oncology. Nature. 2013.
22. Hyman DM, et al. Precision medicine in oncology. Nat Rev Clin Oncol. 2017.
23. Malone ER, et al. Molecular profiling for precision cancer therapy. Genome Med. 2020.
24. Merker JD, et al. Circulating tumor DNA analysis. J Clin Oncol. 2018.
25. Wan JCM, et al. Liquid biopsies in cancer. Nat Rev Cancer. 2017.
26. Heitzer E, et al. Circulating tumor DNA as a liquid biopsy. Nat Rev Genet. 2019.
27. Bettegowda C, et al. Detection of circulating tumor DNA. Sci Transl Med. 2014.
28. Tie J, et al. Circulating tumor DNA for monitoring colorectal cancer. Sci Transl Med. 2016.
29. Le DT, et al. Mismatch repair deficiency predicts immunotherapy response. NEJM. 2015.
30. Goodman AM, et al. Tumor mutational burden and immunotherapy response. Mol Cancer Ther. 2017.
31. Rizvi NA, et al. Mutational landscape determines sensitivity to PD-1 blockade. Science. 2015.
32. Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy. Nat Genet. 2019.
33. Topalian SL, et al. Immune checkpoint blockade. Cancer Cell. 2015.
34. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy. Science. 2015.
35. Chapman PB, et al. BRAF inhibition in melanoma. NEJM. 2011.
36. Flaherty KT, et al. Improved survival with BRAF inhibitors. NEJM. 2012.
37. Mok TS, et al. EGFR mutation and targeted therapy in lung cancer. NEJM. 2009.
38. Paez JG, et al. EGFR mutations in lung cancer. Science. 2004.
39. Slamon DJ, et al. HER2 amplification and trastuzumab therapy. NEJM. 2001.
40. Canon J, et al. KRAS G12C inhibitors. Nature. 2019.
41. Druker BJ, et al. BCR-ABL targeting in leukemia. NEJM. 2001.
42. Sawyers CL. Targeted cancer therapy. Nature. 2004.
43. Swanton C. Intratumor heterogeneity. Science. 2012.
44. Gerlinger M, et al. Tumor heterogeneity evolution. NEJM. 2012.
45. Navin NE. Tumor evolution and heterogeneity. Genome Res. 2015.
46. Tirosh I, et al. Single-cell RNA sequencing in tumors. Science. 2016.
47. Patel AP, et al. Single-cell profiling in glioblastoma. Science. 2014.
48. Hasin Y, et al. Multi-omics approaches. Genome Biol. 2017.
49. Kourou K, et al. Machine learning in cancer prognosis. Comput Struct Biotechnol J. 2015.
50. Esteva A, et al. Deep learning in oncology. Nature. 2019.
51. Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016.
52. Dawson MA, Kouzarides T. Cancer epigenetics. Cell. 2012.
53. Jones PA, Baylin SB. DNA methylation in cancer. Cell. 2007.
54. Esteller M. Epigenetics in cancer. NEJM. 2008.
55. Garraway LA, Janne PA. Circumventing cancer drug resistance. Cancer Discov. 2012.
56. Holohan C, et al. Mechanisms of resistance in cancer therapy. Nat Rev Cancer. 2013.
57. Turajlic S, Swanton C. Metastasis and genomic evolution. Nature. 2016.
58. McGranahan N, Swanton C. Clonal heterogeneity and immune response. Cell. 2017.
59. Yates LR, Campbell PJ. Evolution of cancer genomes. Nat Rev Genet. 2012.
60. Martincorena I, Campbell PJ. Somatic mutation in cancer. Cell. 2015.
61. Beroukhim R, et al. Copy number alterations in cancer. Nature. 2010.
62. Stephens PJ, et al. Complex genomic rearrangements. Cell. 2011.
63. Nik-Zainal S, et al. Mutational processes in breast cancer. Nature. 2012.
64. Helleday T, et al. DNA repair pathways in cancer. Nat Rev Cancer. 2008.
65. Lord CJ, Ashworth A. PARP inhibitors and synthetic lethality. Science. 2017.
66. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016.
67. Ashley EA. The precision medicine revolution. JAMA. 2015.
68. Collins FS, Varmus H. A new initiative on precision medicine. NEJM. 2015.
69. Chakravarty D, et al. OncoKB precision oncology knowledge base. JCO Precis Oncol. 2017.
70. Malone ER, et al. Molecular profiling for precision cancer therapies. Genome Med. 2020.
71. Genetics and Genomics in Cancer: Key Facts Everyone Should Know. OneDayMD.com, 2025.
72. Qiao D, et al. Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives. Cells. 2025.
73. Rituraj, Pal RS, Wahlang J, et al. Precision oncology: transforming cancer care through personalized medicine. Med Oncol. 2025;42:246.
74. Fierce Pharma / Technology Networks. ASCO 2026: precision oncology's implementation era and decentralized NGS testing. June 2026.
75. Stein RC, et al. First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in ER-positive, HER2-negative early breast cancer. J Clin Oncol. 2026;44(16_suppl):500. ASCO 2026 Annual Meeting.
76. OncLive / CURE / OncoDaily / ASCO Daily News coverage of the OPTIMA trial. May–June 2026.
77. DeciBio. Liquid Biopsy May Round-Up 2026: Signatera CDx, Guardant360 Liquid CDx, and NHS-Galleri interim results. 2026.
78. GRAIL. NHS-Galleri trial full results presented at the 2026 ASCO Annual Meeting. June 2026.
79. The Pathologist. ASCO 2026: FDA-cleared AI put to the test — Artera AI Breast in the SWOG 8814 cohort. June 2026.
80. GeneOnline News. AACR 2026 highlights: Path-IO deep learning model for immunotherapy optimization in lung cancer. April 2026.
81. ASCO Post. AI use in cancer diagnosis, prognosis, and treatment — the PERCEPTION single-cell drug-response model. March 2026.
82. NBC News / Baptist Health. Five-year KEYNOTE-942 data: personalized mRNA vaccine (mRNA-4157/V940) plus pembrolizumab in high-risk melanoma, presented at ASCO 2026 and published in J Clin Oncol. June 2026.
83. Weintraub K. mRNA-4157/V940 five-year follow-up analysis. J Clin Oncol. 2026.
84. Memorial Sloan Kettering Cancer Center. Investigational pancreatic cancer mRNA vaccine (autogene cevumeran) shows lasting results in phase 1 follow-up. April 2026.
85. Balachandran VP, et al. Long-term follow-up of personalized mRNA neoantigen vaccine in resected pancreatic ductal adenocarcinoma. 2026.

Medical Disclaimer: This article is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Genomic testing, targeted therapy selection, MRD monitoring, and clinical trial eligibility are highly individual decisions that depend on cancer type, stage, prior treatment, and overall health. Always consult a qualified oncologist or certified genetic counselor before making decisions about testing or treatment. This is a sensitive health topic; if you or someone you know is processing a new cancer diagnosis and finding it difficult to cope, consider reaching out to a licensed counselor or your care team's support services.